BioCentury | Feb 12, 2021
Deals

Feb. 11 Quick Takes: First day pop for Bioventus; plus venture rounds for Pipeline, Immunai, Sanofi, i2O, AZ’s trimmings, Truveta

...approved for cutaneous squamous cell carcinoma.Sanofi taps i2O to try oral NanobodiesSanofi is turning to i2O Therapeutics Inc....
...follow-on insulin lispro (Generic), SAR342434 (Compound #), Insulin lispro Sanofi (Other), Admelog (Other) Immunai Bioventus Inc. Pipeline Therapeutics Inc. i2o Therapeutics Inc. AstraZeneca...
BioCentury | Apr 15, 2020
Finance

April 14 Quick Takes: Digital Dx play Perspectum raises $36M; plus Akeso’s IPO terms, 54gene, i2O and Immunovant

...raised $4.5 million in a seed round in July. Harvard spinout i2O closes seed round i2O Therapeutics Inc....
Items per page:
1 - 2 of 2
BioCentury | Feb 12, 2021
Deals

Feb. 11 Quick Takes: First day pop for Bioventus; plus venture rounds for Pipeline, Immunai, Sanofi, i2O, AZ’s trimmings, Truveta

...approved for cutaneous squamous cell carcinoma.Sanofi taps i2O to try oral NanobodiesSanofi is turning to i2O Therapeutics Inc....
...follow-on insulin lispro (Generic), SAR342434 (Compound #), Insulin lispro Sanofi (Other), Admelog (Other) Immunai Bioventus Inc. Pipeline Therapeutics Inc. i2o Therapeutics Inc. AstraZeneca...
BioCentury | Apr 15, 2020
Finance

April 14 Quick Takes: Digital Dx play Perspectum raises $36M; plus Akeso’s IPO terms, 54gene, i2O and Immunovant

...raised $4.5 million in a seed round in July. Harvard spinout i2O closes seed round i2O Therapeutics Inc....
Items per page:
1 - 2 of 2